Kane Biotech Completes Pilot Manufacturing Phase of StrixNB™ Oral Care Product
WINNIPEG, MB. (October 10, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has successfully developed the manufacturing process…
Kane Biotech Announces Extension of Term of Warrants
WINNIPEG, MB. (October 2, 2012) – Kane Biotech Inc. (TSX-V:KNE) (the “Company”), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms announces that it has amended the terms of its 19,926,328 warrants (the “Warrants”)…
Kane Biotech and the U.S Army Institute of Surgical Research Sign Cooperative Research and Development Agreement
WINNIPEG, MB. (October 1, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces that a Cooperative Research and Development Agreement (CRADA) has just been signed…
Kane Biotech Issued New Patent in Japan
WINNIPEG, MB. (September 24, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.4999842) entitled “Antimicrobial compositions for…
Kane Biotech Commences Veterinary Clinic Testing of StrixNB™ Pet Oral Care Product
WINNIPEG, MB. (September 19, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces veterinary clinic testing of the company’s StrixNB pet oral care product is…
Kane Biotech Announces Changes to the Board of Directors
WINNIPEG, MB. (September 17, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces the appointment of Gord Froehlich to the Company’s Board of Directors and…
Kane Biotech Presents Innovation at 2012 Kansas City Animal Health Investment Forum
WINNIPEG, MB. (August 28, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, presents at the fourth annual KC Animal Health Investment Forum today, showcasing its…
Kane Biotech Announces Grant of Options and Updates Investor Relations Agreement
WINNIPEG, Manitoba (July 9, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, announces that the Company has granted an aggregate of 1,032,500 stock options at…
Kane Biotech Announces Board Members
WINNIPEG, Manitoba (July 03, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company’s Annual and Special Meeting of shareholders…
Kane Biotech Files PCT Patent on Bone Tissue Regeneration Technology
Highlights:
Research study demonstrates bone regenerating activity Global annual market for bone tissue regeneration is over $32 billion
WINNIPEG, Manitoba (May 30, 2012) – – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products…